Trial Profile
A Phase III Open-Label Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of MK0518/Raltegravir in a Diverse Cohort of HIV-Infected Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms REALMRK
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 19 Sep 2011 Results were presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011).
- 19 Sep 2011 Trial acronym (REALMRK) reported by Merck.
- 25 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.